Analytical Data
-
Gene name
HCCA2
- Application
-
Alternative Names
HCCA2; HCCA2 gene; HCCA2 protein; MOB kinase activator 2; MOB2; Mob2 homolog; MOB2 Mps One Binder homolog; MOB2_HUMAN; Mps one binder kinase activator like 2; Mps one binder kinase activator-like 2
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q70IA6
-
Expression Region
1-237aa
-
AA Sequence
MDWLMGKSKAKPNGKKPAAEERKAYLEPEHTKARITDFQFKELVVLPREIDLNEWLASNTTTFFHHINLQYSTISEFCTGETCQTMAVCNTQYYWYDERGKKVKCTAPQYVDFVMSSVQKLVTDEDVFPTKYGREFPSSFESLVRKICRHLFHVLAHIYWAHFKETLALELHGHLNTLYVHFILFAREFNLLDPKETAIMDDLTEVLCSGAGGVHSGGSGDGAGSGGPGAQNHVKER
-
Molecular Weight
53.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HCCA2 recombinant protein has garnered significant interest in the field of immunology and molecular biology due to its potential applications in vaccine development and therapeutic interventions. HCCA2, an antigen typically associated with certain pathogenic bacteria, plays a critical role in eliciting immune responses. The study of HCCA2 is driven by its ability to enhance the recognition of these pathogens by the immune system, thereby contributing to the development of more effective vaccines. Recent advances in recombinant DNA technology have enabled the production of HCCA2 in heterologous expression systems, allowing for large-scale generation of purified protein suitable for research and clinical applications. Investigations into the structural and functional properties of HCCA2 recombinant protein have revealed insights into its immune epitopes and mechanisms of action, paving the way for innovative strategies in vaccine design targeting specific infectious diseases. Furthermore, ongoing research is focused on understanding how HCCA2 can be utilized in combination with adjuvants to boost immune responses, particularly in populations at high risk for infection. Through these studies, HCCA2 recombinant protein represents a promising avenue for enhancing public health outcomes by improving vaccine efficacy and broadening immunological protection against various pathogens.
